Further, because eIF4E phosphorylation is related to chemotherapy resistance in several gynecological malignancies, particularly DNA‐damaging agents [35, 36], concomitant treatment with pharmacological inhibitors of eIF4E could meaningfully improve the survival rate of patients with relapsed cervical cancer exhibiting chemotherapy resistance. This evidence concerns the gene EIF4E and cervical carcinoma.